
zzso zzso zzso a zzso folate zzso has been evaluated clinically on several zzso We studied zzso given as an zzso zzso over zzso zzso every 3 weeks in 44 patients with advanced solid zzso it was given at doses ranging from 20 to 275 zzso The zzso tolerated dose zzso on this schedule is 220 zzso which we also recommend as a starting dose for phase II studies in patients without extensive prior zzso Because of wide individual differences in drug zzso dose escalation in zzso increments is recommended for zzso zzso The principal zzso toxicity was zzso although in some patients a zzso syndrome precluded dose zzso zzso rash and zzso also frequently occurred in toxic zzso zzso plasma zzso were measured after the first dose and the data were fit by two- or zzso zzso zzso zzso The zzso clearance rate was zzso zzso 21 zzso per zzso and did not change with zzso zzso with increasing dose were apparent in the zzso volume of distribution zzso and in the terminal disposition zzso zzso The difference between zzso and zzso zzso counts was correlated with zzso dose zzso zzso zzso P zzso zzso and with the area under the concentration vs time curve zzso zzso zzso zzso P zzso zzso zzso plasma zzso zzso correlated zzso with the zzso white blood count zzso zzso zzso P zzso zzso zzso schedules for the administration of zzso have not been established and phase II trials using both zzso and daily X 5 schedules are under zzso 

